Mortality during the SARS-CoV-2 Pandemic: A Comparative Analysis between Lombardy in Italy and Israel
- PMID: 39200908
- PMCID: PMC11355292
- DOI: 10.3390/jcm13164766
Mortality during the SARS-CoV-2 Pandemic: A Comparative Analysis between Lombardy in Italy and Israel
Abstract
Background: This retrospective study contrasts the impact of the SARS-CoV-2 pandemic in Lombardy (Italy) and Israel, focusing on mortality, healthcare response, public health measures, and demographics. Methods: We analyzed SARS-CoV-2 data from Lombardy and Israel covering four viral waves. Data included infection rates, hospitalizations, and mortality. In Lombardy, healthcare data were collected from the administrative database of the Lombardy Welfare Directorate; in Israel, they were collected from Clalit Health Services and the Israeli Ministry of Health's COVID-19 database. Statistical analyses compared trends in infection rates, demographics, and mortality rates across the four viral waves by using logistic and linear regression models and adjusting for age, sex, and comorbidities. Results: Lombardy exhibited significantly higher SARS-CoV-2 infections and COVID-19 hospitalization rates during the first wave than Israel, with 71,558 cases over a population sample of ~10 million versus 5741 over a population sample of ~4.7 million in Israel. The majority of cases in Israel were managed at home, with 18 cases only (0.3%) requiring intensive care unit (ICU) hospitalization during the first wave, compared to 4104 (5.7%) cases in Lombardy. Israel's vaccination campaign began earlier, so that by the fourth wave, 439,545 (42.2%) people in Israel were fully vaccinated with three doses, compared to 214,542 (22.9%) in Lombardy. Mortality decreased over time in both sites, dropping from 103 cases (1.8%) to 1550 (0.1%) in Israel and from 13,372 (18.7%) to 4388 (0.3%) in Lombardy. Conclusions: Early public health interventions and vaccination were crucial in managing the SARS-CoV-2 impact.
Keywords: Israel; Lombardy; SARS-CoV-2; mortality; vaccine.
Conflict of interest statement
The authors declare no conflicts of interest.
Similar articles
-
Two years of SARS-CoV-2 pandemic and COVID-19 in Lombardy, Italy.Intern Emerg Med. 2023 Aug;18(5):1445-1451. doi: 10.1007/s11739-023-03315-7. Epub 2023 Jun 14. Intern Emerg Med. 2023. PMID: 37314640
-
Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study.Lancet Infect Dis. 2022 Mar;22(3):357-366. doi: 10.1016/S1473-3099(21)00566-1. Epub 2021 Sep 22. Lancet Infect Dis. 2022. PMID: 34562375 Free PMC article.
-
Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy.JAMA. 2020 Apr 28;323(16):1574-1581. doi: 10.1001/jama.2020.5394. JAMA. 2020. PMID: 32250385 Free PMC article.
-
Changes in infectivity, severity and vaccine effectiveness against delta COVID-19 variant ten months into the vaccination program: The Israeli case.Prev Med. 2022 Jan;154:106890. doi: 10.1016/j.ypmed.2021.106890. Epub 2021 Nov 17. Prev Med. 2022. PMID: 34800471 Free PMC article.
-
Epidemiological assessment of the first COVID-19 epidemic wave in Lombardy. A systematic review.Acta Biomed. 2021 Oct 7;92(S6):e2021462. doi: 10.23750/abm.v92iS6.12340. Acta Biomed. 2021. PMID: 34739453 Free PMC article.
References
-
- GBD 2021 Demographics Collaborators Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the COVID-19 pandemic: A comprehensive demographic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403:1989–2056. doi: 10.1016/S0140-6736(24)00476-8. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous